June 18, 2018—Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content, which now covers 120 fully optimized cancer-related genes. OGT’s solid tumor and hematology custom panel content enables users to sequence genes and regions relevant to their cancer research. The preoptimized panel content aims to facilitate the development of robust NGS assays, whether these are working with challenging sample types, such as FFPE tissue, or on difficult to sequence genes, either due to their high guanine-cytosine content or areas of the genome repetitive by nature, such as internal tandem duplications.
Researchers can select content from a range of available NGS panel content available for solid tumors covering breast cancer, colorectal cancer, glioma, lung cancer, melanoma, ovarian cancer, prostate cancer, and sarcoma. For hematology malignancies, the panel content covers acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasm, myelodysplastic syndromes, and myeloid malignancies.
“Our ever-increasing custom panel content along with NGS-specific software development highlights our commitment to providing customers with the best performing and most convenient NGS products on the market. It also shows how responsive we are as a company and that we have listened to the needs of our customers with respect to the additional capabilities of our data analysis pipeline to accompany our panels—which we expect to deliver very soon,” Dave Cook, senior product manager at OGT, said in a statement.